Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.

[1]  A. Esquela-Kerscher,et al.  The complexities of microRNA regulation: mirandering around the rules. , 2010, The international journal of biochemistry & cell biology.

[2]  P. Morin,et al.  MicroRNAs in ovarian carcinomas. , 2010, Endocrine-related cancer.

[3]  D. Clarke‐Pearson,et al.  Clinical practice. Screening for ovarian cancer. , 2009, The New England journal of medicine.

[4]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[5]  Zhihui Feng,et al.  A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. , 2009, Gynecologic oncology.

[6]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[7]  Jian-Bing Fan,et al.  Evaluation of a new high-dimensional miRNA profiling platform , 2009, BMC Medical Genomics.

[8]  F. Slack,et al.  rna interference and micro rna –oriented therapy in cancer: rationales, promises, and challenges , 2009, Current oncology.

[9]  S. Rosenwald,et al.  Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. , 2009, Gynecologic oncology.

[10]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[11]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[12]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[13]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[14]  H. Dressman,et al.  MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. , 2009, Gynecologic oncology.

[15]  E. Wentzel,et al.  Cell–cell contact globally activates microRNA biogenesis , 2009, Proceedings of the National Academy of Sciences.

[16]  S. Wyman,et al.  Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries , 2009, PloS one.

[17]  G. Packham,et al.  MicroRNAs: key players in carcinogenesis and novel therapeutic targets. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  C. Croce,et al.  MiRNAs and cancer. , 2009, The American journal of pathology.

[19]  M. Peter.  Let-7 and miR-200 microRNAs: Guardians against pluripotency and cancer progression , 2009, Cell cycle.

[20]  A. Tomassetti,et al.  E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells , 2009, Oncogene.

[21]  Michael A. Beer,et al.  Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation , 2009, Proceedings of the National Academy of Sciences.

[22]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[23]  F. Slack,et al.  MicroRNA in cancer prognosis. , 2008, The New England journal of medicine.

[24]  Jan-Fang Cheng,et al.  Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.

[25]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[26]  A. Addario,et al.  Role of microRNAs in drug-resistant ovarian cancer cells. , 2008, Gynecologic oncology.

[27]  Kylie L. Gorringe,et al.  Genetic Analysis of Cancer-Implicated MicroRNA in Ovarian Cancer , 2008, Clinical Cancer Research.

[28]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  D. Bartel,et al.  MicroRNAs in the Hox network: an apparent link to posterior prevalence , 2008, Nature Reviews Genetics.

[30]  S. Cannistra,et al.  Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.

[31]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[32]  David C. Corney,et al.  MicroRNA and ovarian cancer. , 2008, Histology and histopathology.

[33]  Dixie L. Mager,et al.  MiRNAs, epigenetics, and cancer , 2008, Mammalian Genome.

[34]  Cicek Gercel-Taylor,et al.  MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. , 2008, Gynecologic oncology.

[35]  Hongbing Shen,et al.  Genetic variants of miRNA sequences and non-small cell lung cancer survival. , 2008, The Journal of clinical investigation.

[36]  Tian-Li Wang,et al.  MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer , 2008, PloS one.

[37]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[38]  M. Korpal,et al.  The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2* , 2008, Journal of Biological Chemistry.

[39]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[40]  M. Birrer,et al.  Genomic analysis of epithelial ovarian cancer , 2008, Cell Research.

[41]  Jae Hoon Kim,et al.  MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.

[42]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[43]  Stephen P Finn,et al.  Potential role of miR-9 and miR-223 in recurrent ovarian cancer , 2008, Molecular Cancer.

[44]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[45]  Ie-Ming Shih,et al.  Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[46]  T. Leung,et al.  Detection and characterization of placental microRNAs in maternal plasma. , 2008, Clinical chemistry.

[47]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[49]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[50]  M. Quinn,et al.  Epithelial–mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm , 2007, Journal of cellular physiology.

[51]  D. Katsaros,et al.  Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. , 2007, Cancer research.

[52]  Sun-Mi Park,et al.  Let-7 Prevents Early Cancer Progression by Suppressing Expression of the Embryonic Gene HMGA2 , 2007, Cell cycle.

[53]  Gregory J. Hannon,et al.  microRNAs join the p53 network — another piece in the tumour-suppression puzzle , 2007, Nature Reviews Cancer.

[54]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[55]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[56]  E. Kistner,et al.  Let-7 expression defines two differentiation stages of cancer , 2007, Proceedings of the National Academy of Sciences.

[57]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Canevari,et al.  Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment , 2007, Molecular Cancer Therapeutics.

[59]  M. Gariboldi,et al.  Molecular predictors of response and outcome in ovarian cancer. , 2006, Critical reviews in oncology/hematology.

[60]  J. Nevins,et al.  Linking oncogenic pathways with therapeutic opportunities , 2006, Nature Reviews Cancer.

[61]  Tara L. Naylor,et al.  microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Peter A. Jones,et al.  Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. , 2006, Cancer cell.

[63]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[64]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Ying,et al.  Entanglement is not necessary for perfect discrimination between unitary operations. , 2006, Physical review letters.

[66]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[67]  Gordon B Mills,et al.  Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon , 2005, Clinical Cancer Research.

[68]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[69]  Wenjun Cheng,et al.  Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract , 2005, Nature Medicine.

[70]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[72]  Joanna H Shih,et al.  Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways , 2004, Oncogene.

[73]  Luigi Marchionni,et al.  Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 , 2004, Oncogene.

[74]  S. Canevari,et al.  CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma , 2004, Clinical Cancer Research.

[75]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[76]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[77]  D. Bartel,et al.  MicroRNA-Directed Cleavage of HOXB8 mRNA , 2004, Science.

[78]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[79]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[80]  A. Jazaeri,et al.  Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[82]  R. L. Baldwin,et al.  Molecular similarities between primary peritoneal and primary ovarian carcinomas , 2003, International Journal of Gynecologic Cancer.

[83]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[84]  K. Sundfeldt.  Cell–cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule , 2003, Molecular and Cellular Endocrinology.

[85]  M. Fraga,et al.  The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2003, Journal of Cell Science.

[86]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[87]  M. Nieto,et al.  The snail superfamily of zinc-finger transcription factors , 2002, Nature Reviews Molecular Cell Biology.

[88]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[89]  M. Wells,et al.  Precursor lesions of ovarian epithelial malignancy , 2001, Histopathology.

[90]  B. Davidson.  Ovarian Carcinoma and Serous Effusions. Changing Views Regarding Tumor Progression and Review of Current Literature , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[91]  B. Reinhart,et al.  Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA , 2000, Nature.

[92]  F. Slack,et al.  The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. , 2000, Molecular cell.

[93]  M. Bookman,et al.  Second-line treatment of ovarian cancer. , 2000, The oncologist.

[94]  A. Børresen-Dale,et al.  Re‐expression of E‐cadherin, α‐catenin and β‐catenin, but not of γ‐catenin, in metastatic tissue from breast cancer patients , 2000 .

[95]  M. Parmar,et al.  First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. , 1998, British Journal of Cancer.

[96]  S. Enerbäck,et al.  E‐cadherin expression in human epithelial ovarian cancer and normal ovary , 1997, International journal of cancer.

[97]  S. Finkelstein,et al.  A case‐matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma , 1997, Cancer.

[98]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[99]  B. Karlan,et al.  Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. , 2010, Gynecologic oncology.

[100]  Hansjuerg Alder,et al.  The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. , 2009, Gynecologic oncology.

[101]  J. Tostain,et al.  Elevated serum-circulating RNA in patients with conventional renal cell cancer. , 2008, Anticancer research.

[102]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006 .